# A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

> **NCT00824590** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 20 (actual)

## Conditions studied

- Alzheimer's Disease
- Huntington's Disease

## Interventions

- **DRUG:** Dimebon
- **DRUG:** Dimebon

## Key facts

- **NCT ID:** NCT00824590
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2009-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00824590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00824590, "A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00824590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*